EC Pharmacology and Toxicology

AIDS and the human immunodeficiency virus (HIV) have risen to the status of main causes of death and disease morbidity in the developed world since their discovery in the early 1980s. In light of the first discovery and more than 78 million individuals have contracted the disease, and more than 39 million people have died from AIDS-related complications. Since the peak in 2005, AIDS-related mortality have decreased by 35 percent. There have been six human trials of HIV vaccine effectiveness. In spite of the fact that there are numerous effective prevention and treatment options, researchers have long been enthusiastic about HIV vaccine as the ultimate solution for HIV prevention and control. AIDS was found to be caused by HIV. It's been announced that an AIDS vaccine would be tested within two years by the United States' HHS Secretary Margaret Heckler.

Keywords: AIDS; HIV-1; Six Human Trials; Future Directions; Challenges Faced

1. Rubens M., et al. “HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions”. Journal of Immunology Research (2015): 560347.
2. Pollara J., et al. “Lessons Learned from Human HIV Vaccine Trials”. Current Opinion in HIV and AIDS3 (2017): 216-221.
3. History of HIV Vaccine Research | NIH: National Institute of Allergy (2022).
4. Escolano A., et al. “Progress Toward Active or Passive HIV-1 Vaccination”. Journal of Experimental Medicine 1 (2016): 3-16.
5. Casazza JP., et al. “Therapeutic Vaccination Expands and Improves the Function of the HIV-Specific Memory T-Cell Repertoire”. The Journal of Infectious Diseases12 (2013): 1829-1840.
6. Shu J., et al. “Designing Peptide-Based HIV Vaccine for Chinese”. BioMed Research International (2014): 272950.
7. Moodley N., et al. “The Case for Adolescent HIV Vaccination in South Africa”. Medicine4 (2016): e2528.
8. “MRNA Vaccines Offer Hope for HIV”. Nature Medicine (2022).
9. Hudgens M., et al. “Power to Detect the Effects of HIV Vaccination in Repeated Low‐Dose Challenge Experiments”. The Journal of Infectious Diseases4 (2009): 609-613.
10. Song XT., et al. “An Alternative and Effective HIV Vaccination Approach Based on Inhibition of Antigen Presentation Attenuators in Dendritic Cells”. PLoS Medicine1 (2006): e0030011.
11. Kerneis S., et al. “Long-Term Immune Responses to Vaccination in HIV-Infected Patients: A Systematic Review and Meta-Analysis”. Clinical Infectious Diseases8 (2014): 1130-1139.
12. Cram JA., et al. “Human Gut Microbiota Is Associated With HIV-Reactive Immunoglobulin at Baseline and Following HIV Vaccination”. PLOS ONE12 (2019): e0225622.
13. Klatt NR., et al. “Effects of Persistent Modulation of Intestinal Microbiota on SIV/HIV Vaccination in Rhesus Macaques”. Npj Vaccines 6 (2021): 34.
14. Hargrave A., et al. “Current Status of HIV-1 Vaccines”. Vaccines9 (2021): 1026.